high grade B-cell lymphoma

Summary

high grade B-cell lymphoma (MONDO:0044889) is a cancer and 93 clinical trials. Top therapeutic interventions include rituximab, axicabtagene ciloleucel, and epcoritamab. A subtype of diffuse large B-cell lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 93

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	high grade B-cell lymphoma
Mondo ID	MONDO:0044889
NCIT	C138211
SNOMED CT	277617004
UMLS	C0456863
MedGen	629622
GARD	0025919
Is cancer (heuristic)	yes

Also known as: HGBL · high grade B-cell lymphoma · high-grade B-cell lymphoma

Disease family

This is a subtype of diffuse large B-cell lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › diffuse large B-cell lymphoma › high grade B-cell lymphoma

Related subtypes (29): relapsed/refractory diffuse large B-cell lymphoma, breast diffuse large B-cell lymphoma, colorectal diffuse large B-cell lymphoma, gastric diffuse large B-cell lymphoma, liver diffuse large B-cell lymphoma, primary cutaneous diffuse large B-cell lymphoma, Leg type, primary pulmonary diffuse large B-cell lymphoma, small intestinal diffuse large B-cell lymphoma, splenic diffuse large B-cell lymphoma, thyroid gland diffuse large B-cell lymphoma, Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly, plasmablastic lymphoma, diffuse large B-cell lymphoma of the central nervous system, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma with chronic inflammation, ALK-positive large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, primary mediastinal large B-cell lymphoma, intravascular large B-cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, BN2 diffuse large B-cell lymphoma, EZB diffuse large B-cell lymphoma, MCD diffuse large B-cell lymphoma, N1 diffuse large B-cell lymphoma, ST2 diffuse large B-cell lymphoma, A53 diffuse large B-cell lymphoma, primary vitreoretinal large b-cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 93.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	27
PHASE1	27
PHASE1/PHASE2	20
Not specified	17
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07502118	PHASE2/PHASE3	RECRUITING	NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
NCT03620578	PHASE2	ACTIVE_NOT_RECRUITING	DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
NCT03625037	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03995147	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
NCT04257578	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
NCT04479267	PHASE2	ACTIVE_NOT_RECRUITING	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
NCT04542824	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04745559	PHASE2	ACTIVE_NOT_RECRUITING	Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
NCT04792489	PHASE2	RECRUITING	DALY II USA/ MB-CART2019.1 for DLBCL
NCT04836507	PHASE1/PHASE2	RECRUITING	Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
NCT04914741	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
NCT05025800	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
NCT05256641	PHASE1/PHASE2	RECRUITING	Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
NCT05263583	PHASE2	ACTIVE_NOT_RECRUITING	Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
NCT05455697	PHASE1/PHASE2	RECRUITING	Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
NCT05507541	PHASE2	ACTIVE_NOT_RECRUITING	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05672251	PHASE2	RECRUITING	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05890352	PHASE2	RECRUITING	Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
NCT06093841	PHASE2	ACTIVE_NOT_RECRUITING	Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06249191	PHASE1/PHASE2	RECRUITING	Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
NCT06271057	PHASE2	RECRUITING	Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
NCT06287398	PHASE2	RECRUITING	Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
NCT06343311	PHASE1/PHASE2	RECRUITING	T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
NCT06458439	PHASE2	RECRUITING	Epcoritamab-CAR T Cells for Large B-cell Lymphomas
NCT06533579	PHASE1/PHASE2	RECRUITING	Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06550141	PHASE2	RECRUITING	Emapalumab Prevention of CAR-T Cell Associated Toxicities
NCT06736613	PHASE2	RECRUITING	A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
NCT06765317	PHASE2	RECRUITING	A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
NCT06784726	PHASE2	RECRUITING	Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
NCT06918912	PHASE2	RECRUITING	Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
NCT07098364	PHASE1/PHASE2	RECRUITING	ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
NCT07197307	PHASE2	NOT_YET_RECRUITING	Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07473167	PHASE1/PHASE2	RECRUITING	Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
NCT07502872	PHASE2	NOT_YET_RECRUITING	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
NCT01859819	PHASE2	COMPLETED	Treatment for Advanced B-Cell Lymphoma
NCT02348216	PHASE1/PHASE2	COMPLETED	Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
NCT02623920	PHASE2	WITHDRAWN	Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT03309878	PHASE1/PHASE2	COMPLETED	Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT03837873	PHASE2	UNKNOWN	DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
NCT04058470	PHASE1/PHASE2	UNKNOWN	Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RITUXIMAB	4	18
AXICABTAGENE CILOLEUCEL	4	8
EPCORITAMAB	4	7
MOSUNETUZUMAB	4	5
POLATUZUMAB VEDOTIN	4	5
LONCASTUXIMAB TESIRINE	4	4
TAFASITAMAB	4	4
GLOFITAMAB	4	3
ACALABRUTINIB	4	2
ANAKINRA	4	2
TISAGENLECLEUCEL	4	2
COPANLISIB	4	1
DENILEUKIN DIFTITOX	4	1
EMAPALUMAB	4	1
FLUDEOXYGLUCOSE F 18	4	1
MOGAMULIZUMAB	4	1
RETIFANLIMAB	4	1
TAZEMETOSTAT	4	1
TORIPALIMAB	4	1
ZANUBRUTINIB	4	1
LISOCABTAGENE MARALEUCEL	3	2
ODRONEXTAMAB	3	2
GOLCADOMIDE	3	1
SEPANTRONIUM	2	3
EFINEPTAKIN ALFA	2	1
FIMEPINOSTAT	2	1
MAPLIRPACEPT	2	1
ONTORPACEPT	2	1
RIMIDUCID	2	1
VEVOCTADEKIN	2	1